On Wednesday, Following Stocks were among the “Top Gainers” of U.S. Stock Market: Esperion Therapeutics, (NASDAQ:ESPR), Great Basin Scientific, (NASDAQ:GBSN), Midway Gold, (NYSEMKT:MDW), BioCryst Pharmaceuticals, (NASDAQ:BCRX)
Esperion Therapeutics, (NASDAQ:ESPR), with shares gained 13.65%, closed at $105.24.
Great Basin Scientific, (NASDAQ:GBSN), with shares jumped 12.82%, settled at $4.40.
Midway Gold, (NYSEMKT:MDW), with shares climbed 10.94%, and closed at $0.35.
BioCryst Pharmaceuticals, (NASDAQ:BCRX), gained 10.63%, and closed at $9.99.
Latest NEWS regarding these Stocks are depicted underneath:
Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Esperion Therapeutics, Inc. (ESPR), gained during its last trading session as UBS initiated coverage of Esperion stock with a buy rating, praising its cholesterol drug candidate. Analyst Andrew Peters wrote that ETC-1002, a drug lowering LDL cholesterol that yielded positive phase 2b trial results last month, could present further upside even for a stock that’s already more than doubled this year.
The company formerly on March 24, declared the closing of its follow-on public offering of 2,012,500 shares of ordinary stock, offered at a price to the public of $100.00 per share, which comprises the exercise in full by the underwriters of their option to purchase 262,500 additional shares of ordinary stock. This exercise brings the net proceeds in the offering to $189.9 million, after deducting underwriting discounts and commissions and estimated expenses payable by Esperion. Esperion intends to use the net proceeds from the offering, in addition to its other existing capital resources, to complete the clinical development of ETC-1002, counting development of a fixed-dose combination of ETC-1002 and ezetimibe for statin intolerant patients, pre-commercial launch activities for ETC-1002 in the statin intolerant patient population, the initiation of a cardiovascular outcomes trial for high-risk patients who have had a cardiovascular event, working capital, and for general corporate and administrative expenses.
Esperion Therapeutics, Inc., a biopharmaceutical corporation, focuses on the research, development, and commercialization of oral and low-density lipoprotein cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. Its products comprise ETC-1002, an oral molecule therapy that is in Phase 2b clinical trials to treat patients with hypercholesterolemia, in addition to to lower levels of LDL-cholesterol, and avoid various side effects associated with LDL-cholesterol lowering therapies.
Great Basin Scientific, Inc. (NASDAQ:GBSN)
Great Basin Scientific, Inc. (GBSN), inclined Wednesday following the news that United States Patent and Trademark Office (USPTO) issued a patent for the corporation’s sample-to-result molecular diagnostic testing technology on Tuesday.
This newly issued patent further enhances the Corporation’s patent family, which comprises U.S. patent 8,637,250 (issued Jan. 28, 2014) for systems and methods for point-of-care amplification and detection of polynucleotides covering isothermal amplification using HDA on the surface of chips. This patent permits future simplification of Great Basin’s chip technology which would further lower costs, raise speed, and potentially allow for a field-deployable approach for molecular diagnostics. U.S. patent 8,574,833 (issued on Nov. 5, 2013) covers methods and compositions for amplifying a detectable signal. The method, termed AMPED, is a cost-effective approach for direct detection of pathogens present in clinical samples such as blood, lung aspirates, urine, stool and swabs at low levels without the requirement of PCR-based target amplification. Great Basin asserts that by eliminating the amplification step used in other methods, their technology has the potential to provide faster results at a lower cost.
Great Basin Scientific, Inc., a molecular diagnostic testing corporation, doing business as Great Basin Corporation, develops and commercializes molecular diagnostic systems that are designed to test hospital-attained infections.
Midway Gold Corp. (NYSEMKT:MDW)
Midway Gold Corp. (MDW), filed Form 8-K on Regulation FD Disclosure.
Formerly on March 16, the company declared financial results for the period ended December 31, 2014. These results were filed recently with the United States Securities and Exchange Commission in the Corporation’s annual report on Form 10-K and with the relevant securities regulators in Canada.
This week, analysts mean recommendation for this stock is 2.3.
Midway Gold Corp. engages in the attainment, exploration, and development of gold and silver mineral properties in North America. The corporation holds interest in the Pan and Gold Rock Projects located along the prolific Battle Mountain/Eureka gold trend; the Spring Valley property, which is located in the Spring Valley Mining District, Pershing County, Nevada.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
On Tuesday, BioCryst Pharmaceuticals, Inc. (BCRX), declared that the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) has awarded BioCryst a contract for the continued development of BCX4430 as a potential treatment for diseases caused by RNA pathogens, counting filoviruses. This ASPR/BARDA contract comprises a base contract of $12.1 million to support BCX4430 drug manufacturing, in addition to $22.9 million in additional development options that can be exercised by the Government, bringing the potential value of the contract to $35.0 million. Filoviruses represent serious threats to national security and the U.S. Government has made this a top priority for medical countermeasure development.
BioCryst Pharmaceuticals, Inc., a biotechnology corporation, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
